Compare Novartis AG (NVS) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Zillow Group Inc Class A — how do they compare? Novartis AG trades at $143.31 (market cap $268.57B), while Zillow Group Inc Class A trades at $29.56 (market cap $6.59B). The key difference: Novartis AG is far larger — about 40.8× Zillow Group Inc Class A's market cap, and Novartis AG pays a 3.31% dividend while Zillow Group Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Zillow Group Inc Class A for 87 Days on average.
| NVS | ZG | |
|---|---|---|
Market Cap | $268.57B | $6.59B |
Volume | 1,532,573 | 1,361,381 |
Sector | Health | Media |
52-Week High | $168.62 | $74.58 |
52-Week Low | $121.80 | $27.70 |
Typical Hold Time | 82 Days | 87 Days |
Enterprise Value | $309.89B | $6.47B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Zillow Group (ZG) trades at $30.00, up 7.26% over 24 hours, but remains in a technical downtrend with bearish moving average signals. The company reported a return to profitability in 2025 with net income of $23 million, though its P/E ratio of 130 is high. Recent earnings have shown volatility, with a miss in Q4 2025 but beats in subsequent quarters. Analyst sentiment is mixed, with a consensus 'Hold' rating and a price target of $48.87, suggesting significant potential upside from the current price.
The outlook for ZG hinges on execution in a challenging housing market. Opportunities include strong revenue growth and market leadership, but risks involve high valuation, affordability headwinds, and intense competition. The stock appears undervalued relative to analyst targets, but investors must weigh the premium valuation against macroeconomic pressures on the housing sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
